Publication date: Jun 16, 2024
The global SARS-CoV-2 pandemic prompted nations to implement mobility limitations to curb virus spread. In Chile, targeted interregional measures were employed to mitigate the social and economic costs. Here, we employ a novel real-time methodology to assess the impact of such mobility restrictions on epidemic control. Leveraging telecom-derived eXtended Detail Records (XDR) and official COVID-19 epidemiological data, we estimate interregional mobility and disease prevalence. Employing Bayesian adjustments, we compare different mobility restriction scenarios: business-as-usual (BAU), initial measures, and total lockdown. Mobility reductions significantly curtailed cases and risk across regions. Even modest mobility declines under total lockdowns considerably lowered imported cases. The high-risk Santiago Region, a national source of infections to other regions, demonstrated lowered risk due to mobility restrictions. Our approach facilitates rapid regional insights for informed policy responses.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | population |
| disease | IDO | pathogen |
| disease | MESH | infections |
| disease | MESH | COVID-19 |
| disease | VO | time |
| drug | DRUGBANK | Piroxicam |
| disease | VO | age |
| disease | MESH | asymptomatic infections |
| disease | MESH | Coronavirus Infections |
| drug | DRUGBANK | Haloperidol |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Etodolac |
| disease | VO | organization |
| disease | VO | Gap |
| drug | DRUGBANK | Trestolone |
| drug | DRUGBANK | Cysteamine |
| disease | IDO | intervention |
| disease | VO | biological sex |
| disease | IDO | infection |
| disease | VO | Advent |
| disease | IDO | country |
| disease | VO | vaccination |
| drug | DRUGBANK | Huperzine B |
| drug | DRUGBANK | Spinosad |
| disease | VO | effective |
| disease | MESH | death |
| disease | VO | effectiveness |
| disease | IDO | contact tracing |
| disease | MESH | Infectious Diseases |
| disease | IDO | process |